Hypothesis

Method

Team

Portfolio

Disciplined Creation.

Valuable therapeutics require more than capital.

While we may be far removed from the frontlines of care itself, patients and their return to health drives us.

We are motivated by great ideas, devoted people, and deep engagement. Clear-minded leaders see further ahead to realize meaningful ideas, and strive to build value through strategic problem solving. Our people–ideas–strategy perspective hones our approach to investment, leadership, and company creation.

Celosia is therapeutic area-, modality-, and stage-agnostic.

“Efforts and courage are not enough without purpose and direction.”

John F. Kennedy

“I’d rather die deceived by dreams than give My heart to home and trade and never live.”

Attar

“If you buy into a business, you own a business.”

Warren Buffett

“The value of experience is not in seeing much, but in seeing wisely.”

Sir William Osler

“A strategy is like a lever that magnifies force.”

Richard Rumelt

“The best way to predict your future is to create it.”

Abraham Lincoln

“A mighty flame followeth a tiny spark.”

Dante Alighieri

“Let us see how high we can fly before the sun melts the wax in our wings.”

Subrahmanyan Chandrasekhar

“A leader’s most important job is creating and constantly adjusting the strategic bridge between goals and objectives.”

Richard Rumelt

Investment FOCUS

Great therapeutics

are rare.

Skilled problem solvers and courageous leaders drive innovation into the world. The process is continuous, from technical inception and realization, to de-risking for regulatory authorities, and to delivery to providers and patients. Our investment process appreciates this entire lifecycle, associated skills, and intrinsic value, driving investment clarity.

A great therapeutic is rare, and once identified, deeply impactful.

PROACTIVE LEADERSHIP

Successful therapeutics

are willed into existence.

Supporting our partner companies is a privilege we take seriously. By constructively adding our diverse experiences into those of our partners’ management, we deepen and expand business value. Our additive leadership is far less than activism, but far more than passive capital.

We engage our partners on every topic that may support their strategy, including board dialogue, probabilistic scenario analysis, and cellular assay design.

We aim for our actions to bend risk profiles and to clarify roadmaps.

Targeted Creation

Opportunities

require architects.

The understanding of disease and applied technologies evolves at a pace commensurate with our time; contextual clarity is needed to propel knowledge to breakthroughs. At Celosia, we consume knowledge so that we may stand on the shoulders of our predecessors.

We purposefully focus only on a handful of creation opportunities to maximize success. We engage disparate disciplines and take orthogonal approaches with leading scientists.

Our view is that we are cofounders together with the opportunity originators, demanding an ownership mindset from all involved.

“Research is to see what everyone else has seen, and to think what nobody else has thought.”

Albert Szent-Gyorgyi

“The product of the scientific imagination is a new vision of relations—like that of the artistic imagination.”

EB Wilson

“Pleasure to me is wonder—the unexplored, the unexpected, the thing that is hidden and the changeless thing that lurks behind superficial mutability.”

H.P. Lovecraft

“The art and science of asking questions is the source of all knowledge.”

Thomas Berger

“Nothing is so difficult as not deceiving oneself.”

Wittgenstein

”Genius is talent exercised with courage.”

Wittgenstein

“Thoughts without content are empty, intuitions without concepts are blind.”

Immanuel Kant

“Start by doing what’s necessary; then do what’s possible; and suddenly you are doing the impossible.”

Francis of Assisi

“The greatest leader is not necessarily the one who does the greatest things. He is the one that gets the people to do the greatest things.”

Ronald Reagan

TEAM

Pasha Sarraf, MD, PhD

Dr. Pasha Sarraf is a motivated physician-scientist with deep leadership experience across the business of life sciences, from pharma, to biotech, to Wall Street. His incisive decision-making ensures future value creation on every project he works on.

Read Bio

Andrew N Schwartzberg

Andrew Schwartzberg is one of the leading affordable housing developers in the United States and an active investor in companies focused on advancements in the life sciences.

Read Bio

Aaron Day-Williams, PhD

Dr. Aaron Day-Williams is a highly respected and collaborative computational geneticist and biologist who excels at transforming quantitative assessments of therapeutic hypotheses into actionable target identification, validation, and clinical development.

Read Bio

Dylan Dupuis, PhD

Dr. Dylan Dupuis is an experienced biotech analyst who skillfully applies qualitative and quantitative thinking to identify exceptional value in life sciences opportunities.

Read Bio

James Patterson, MD, PhD

Dr. James Patterson is an inventive physician-scientist and networked entrepreneur, skillfully founding, fundraising, and leading R&D efforts to create impactful therapeutics.

Read Bio

Nathan Edwards

Nathan Edwards has deep expertise in tactical and strategic financial management spanning project incubation to commercial launches, with a proactive and disciplined approach to portfolio optimization.

Read Bio

Nathan Post

Nathan Post is an operator experienced in building, scaling, and transforming biotechnology companies across a range of private investment stages.

Read Bio

Tongtong Zhao, PhD

Dr. Tongtong Zhao is a distinguished scientist and biotech innovator whose expertise spans analytical rigor, foundational research, and technology development central to company building.

Read Bio